8-K: Integer Holdings Agrees to $5.7B Acquisition, Q2 Sales Decline

Integer Holdings Corporation announced a definitive agreement to be acquired by an affiliate of KKR for $5.7 billion, while reporting a 2.6% decrease in second-quarter sales.

Summary

• Integer Holdings Corporation reported second quarter 2026 results, with sales decreasing 2.6% to $464 million compared to the prior year's second quarter.
• GAAP operating income from continuing operations fell by 42% to $35 million, and non-GAAP adjusted operating income decreased by 10% to $73 million.
• GAAP income from continuing operations was $24 million, down 36%, while non-GAAP adjusted net income remained flat at $55 million.
• GAAP diluted EPS from continuing operations decreased by 34% to $0.69, but non-GAAP adjusted EPS increased by 3% to $1.60.
• Total debt increased by $53 million to $1.238 billion, resulting in a leverage ratio of 3.2 times adjusted EBITDA.
• The company announced a definitive agreement for an affiliate of KKR to acquire all outstanding shares for $127 per share in cash, valuing the enterprise at $5.7 billion.
• Due to the pending acquisition, the company has withdrawn its financial outlook and canceled its earnings conference call.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative development due to declining sales and operating income, despite the proposed acquisition offering a premium to shareholders.

Positives

• Non-GAAP adjusted net income remained stable, decreasing by only 0.2% to $55 million.
• Non-GAAP adjusted EPS increased by 3.2% to $1.60.
• The proposed acquisition by KKR offers shareholders $127 per share in cash, representing an enterprise value of $5.7 billion.

Negatives

• Total sales decreased by 2.6% to $464 million.
• Organic sales decreased by 1.5%.
• GAAP operating income from continuing operations decreased by 41.8% to $34.5 million.
• Non-GAAP adjusted operating income decreased by 10.2% to $73 million.
• GAAP income from continuing operations decreased by 36.2% to $23.6 million.
• GAAP diluted EPS from continuing operations decreased by 33.7% to $0.69.
• Adjusted EBITDA decreased by 4.1% to $94.9 million.
• Total debt increased by $53 million to $1.238 billion, with a leverage ratio of 3.2 times adjusted EBITDA.

Risks

• The pending acquisition by KKR introduces risks related to the timing and likelihood of completion, including the receipt of regulatory approvals and potential termination of the agreement.
• Disruption of management time from ongoing business operations due to the transaction.
• Adverse effects on the market price of common stock due to announcements related to the transaction.
• Potential adverse effects on business relationships, customer retention, and employee retention due to the transaction and its announcement.
• Unforeseen or unknown liabilities associated with the transaction.
• Potential litigation related to the transaction.
• Third-party contracts may contain provisions that require consent or are impacted by the transaction.
• Significant costs and expenses incurred in connection with the transaction.

Future Outlook

The company has withdrawn its previously issued financial outlook due to the pending acquisition by KKR.

Management Comments

• Integer Holdings Corporation today announced results for the three months ended July 3, 2026.
• In a separate press release issued today, Integer and KKR announced they have entered into a definitive agreement under which an affiliate of investment funds managed by KKR will acquire all of the outstanding shares of Integer in an all-cash transaction valued at an enterprise value of $5.7 billion.
• Under the terms of the agreement, Integer stockholders will receive $127 per share in cash.

Industry Context

StockSavvy.ai notes that the medical device contract development and manufacturing organization (CDMO) sector is experiencing consolidation, with larger private equity firms like KKR actively acquiring companies. The reported sales decline in Cardio & Vascular and Other Markets segments, attributed to product transitions and market exits, is a concern, though the stable adjusted net income and growth in adjusted EPS suggest underlying operational resilience.

Legal Proceedings

• The company is defending a securities class action lawsuit, with $1.8 million of expense incurred in the second quarter of 2026 related to this defense.

Stakeholder Impact

• Shareholders: Will receive $127 per share in cash upon completion of the acquisition by KKR.
• Employees: Potential impact on retention and operations due to the acquisition; specific details not provided.
• Customers: Potential impact on relationships and service continuity due to the acquisition; specific details not provided.
• Suppliers: Potential impact on relationships due to the acquisition; specific details not provided.

Next Steps

• Completion of the acquisition by KKR, subject to customary closing conditions, including stockholder approval and regulatory approvals.
• Withdrawal of previously issued financial outlook.
• Cancellation of the earnings conference call and webcast.

Key Dates

Recommendation

The pending acquisition at a premium provides a clear exit for shareholders, making 'hold' appropriate to await deal closure. The underlying operational decline in Q2 is a concern, but the acquisition price mitigates immediate downside risk for current holders.

Keywords

Integer Holdings, KKR, Acquisition, Medical Device, Contract Development and Manufacturing Organization, CDMO, Cardio & Vascular, Cardiac Rhythm Management